February 13 2019. A study reported on November 28, 2018 in the journal Cancer Epidemiology, Biomarkers & Prevention found a lower risk of dying from prostate cancer among patients who used aspirin.
Elizabeth A. Platz of Johns Hopkins Bloomberg School of Public Health and colleagues analyzed data from 5,060 Caucasian and 1,534 African-American participants in the Atherosclerosis Risk in Communities study who did not have a history of cancer upon enrollment between 1987 and 1989. Information concerning the use of nonsteroidal anti-inflammatory drugs (NSAIDs) was obtained during four study visits conducted from 1987 to 1998. Cancer diagnoses were confirmed through 2012.
There was no association observed between the use of aspirin and the incidence of prostate cancer. Nevertheless, subjects who reporting being aspirin users at the last study visit had a 41% lower risk of dying from the disease in comparison with nonusers. The association was valid for both Caucasian and African American men and was significant for those who used aspirin daily and/or for the prevention of cardiovascular disease. Low dose and regular strength aspirin were both associated with a lower risk of dying from prostate cancer. Among the group of men who used aspirin prior to their prostate cancer diagnosis, there was a 57% adjusted reduction in mortality from the disease in comparison with prostate cancer patients who did not use aspirin, which suggests that the compound may modify the risk of early metastasis. The use of non-aspirin NSAIDs was not associated with prostate cancer mortality.
“This prospective, community-based study of white and black men provides evidence that aspirin may protect against prostate cancer mortality,” the authors conclude. “Additional studies are needed to confirm these findings, build support for a causal relationship, and assess the influence of dose, frequency, and timing of aspirin use.”
Source: https://www.lifeexte...Page-01#aspirin
Edited by Engadin, 15 February 2019 - 04:05 PM.
